Indian shares decline as Fed's hawkish outlook spooks investors
Corrects paragraph 8 to say financials and IT stocks were the top sectoral decliners, not the only sectoral decliners
By Hritam Mukherjee and Kashish Tandon
Dec 19 (Reuters) -Indian shares fell on Thursday after the Federal Reserve forecast fewer interest rate cuts in 2025, souring risk appetite and raising concerns of further outflows, particularly from foreign investors.
The Nifty 50 .NSEI declined 1.02% to 23,951.7 points, while the BSE Sensex .BSESN dropped 1.2% to 79,218.05, with both indexes closing below their 50-day averages for the third straight session.
The Fed delivered a widely expected 25 basis points rate cut but forecast just two reductions in 2025, half of what policymakers anticipated in September.
U.S. rate cuts tend to help emerging markets such as India, as they can boost foreign inflows.
The Fed's hawkish outlook has dampened foreign investors' risk appetite for local equities, two analysts said.
"Lower pace of rate cuts result in foreign investors going into a 'risk-aversion' mode and reduce inflows in emerging markets like India. Hence, markets have seen selling pressure today," said Siddhartha Khemka, head of research of wealth management at Motilal Oswal Financial Services.
Indian benchmarks have lost over 3% each this week and are set for their first weekly decline in five. Foreigners offloaded stocks worth a net 80.06 billion rupees ($941.2 million) up to Wednesday.
Financials .NIFTYFIN and IT stocks .NIFTYIT were the top sectoral decliners, falling 1.2% and 1.3%, respectively.
Indian IT firms are particularly sensitive to U.S. interest rates, as they earn a significant chunk of their revenue from the region.
Metals .NIFTYMET shed 1%, tracking global peers, due to a stronger dollar, which makes it more expensive for other currency holders to buy greenback-priced commodities. MET/L
The more domestically focussed smallcaps .NIFSMCP100 and midcaps .NIFMDCP100 slipped 0.5% and 0.3%, respectively.
ICICI Bank ICBK.NS led losses among the top five Nifty 50 heavyweights, closing 2% lower.
Bucking the trend, generic drugmaker Dr Reddy's Laboratories REDY.NS ended 4% higher after Nomura upgraded the stock to "buy" from "neutral".
Healthcare tech services provider Inventurus Knowledge Solutions INVU.NS ended 48% higher in its trading debut.
($1 = 85.0600 Indian rupees)
Reporting by Hritam Mukherjee and Kashish Tandon in Bengaluru; Editing by Sonia Cheema and Varun H K
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
